Craig-Hallum Reiterates Buy Rating on MapLight Therapeutics, Sets $40 Target
Craig-Hallum maintains its buy rating for MapLight Therapeutics with a $40 price target, a 27.47% upside from the current price.
Key Points
- Craig-Hallum reiterated its buy rating on MapLight Therapeutics with a $40 price target on June 23, 2026.
- Craig-Hallum's $40 price target implies 27.47% upside from MapLight Therapeutics, Inc.'s ($MPLT) current $31.38 share price.
- MapLight Therapeutics trades on the NasdaqGS with a market cap of about $1.35 billion and a 52-week high of $33.28.
- Institutional investors like BlackRock and Goldman Sachs have increased their holdings in MapLight Therapeutics.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Craig-Hallum reiterated its buy rating on MapLight Therapeutics, Inc. (NasdaqGS: MPLT) on June 23, 2026. Analyst Adam Vogel set a price target of $40, reflecting confidence in the company's future prospects.
Craig-Hallum vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in MapLight Therapeutics
Several institutional investors have shown interest in MapLight Therapeutics. BlackRock, Inc. increased its holdings by 244,217 shares, now owning 1,339,731 shares worth approximately $27.2 million, marking a 22.3% increase. Goldman Sachs Group Inc. also expanded its position, adding 57,705 shares to hold 1,994,873 shares valued at about $40.6 million, a 3.0% increase. Blue Owl Capital Holdings LP significantly grew its stake by 678,871 shares, now holding 1,005,929 shares valued at $20.5 million, a remarkable 207.6% increase.
MapLight Therapeutics, Inc. Stock Up 149.0%
Shares of MapLight Therapeutics traded near $30.47 on Tuesday. The company has a market cap of approximately $1.35 billion. Although it isn't currently profitable, the biotechnology firm has an impressive current ratio of 22.91, indicating strong liquidity. The stock's 52-week range is between $12.24 and $33.28, with a 50-day moving average of $28.92 and a 200-day moving average of $21.11.
$MPLT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 23, 2026, Craig-Hallum maintained its buy rating for MapLight Therapeutics with a $40 price target. Needham also maintained its buy rating on June 22, 2026, setting their target at $42. UBS initiated coverage on May 27, 2026, with a buy rating and a $48 target. Overall, the consensus among analysts is a strong buy, with an average target price of $38.7 based on 10 opinions.
About MapLight Therapeutics
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California. It focuses on developing treatments for central nervous system disorders. The company’s pipeline includes products aimed at schizophrenia, Alzheimer's disease psychosis, autism, Parkinson's disease, and other neuropsychiatric conditions. Led by CEO Dr. Christopher A. Kroeger, the firm employs 133 people.
Bottom Line
Craig-Hallum's reiteration of its buy rating for MapLight Therapeutics underscores the firm's confidence in the company's potential. With strong institutional interest and a robust pipeline in the healthcare sector, MapLight remains a company to watch. As always, remember that analyst ratings are based on past performance and expectations, and actual results may vary.
Get MapLight Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MPLT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.